GHK-Cu — the copper complex of the tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys) — is one of the most extensively studied molecules in regenerative research. It is not a synthetic novelty: GHK occurs naturally in human plasma, saliva and urine, and it binds copper(II) with high affinity to form the active GHK-Cu complex. First isolated and described by biochemist Loren Pickart in 1973, it has accumulated more than five decades of laboratory and preclinical study.
What keeps GHK-Cu at the center of copper-peptide research is not a single dramatic effect, but the breadth of the biology it appears to touch. This guide summarizes what the peer-reviewed literature reports — and, just as importantly, where the evidence is still thin.
One reason GHK draws so much interest is that the body makes it — and makes less of it over time. Reviews of the literature report that plasma GHK levels are substantially higher in young adults than in older adults, declining markedly from around age 20 into the 60s. Because GHK is associated with tissue-repair signaling, this age-related decline has been proposed as one factor in the gradual slowing of the body's natural regenerative capacity. This "restoration of a youthful signal" framing is a large part of why GHK-Cu became a reference compound in skin and regeneration research.
The observation that made GHK-Cu genuinely unusual came from gene-expression profiling. Using large-scale transcriptome data (including the Broad Institute's Connectivity Map), researchers reported that GHK could change the expression of roughly 4,000 human genes — raising the activity of a large set and lowering the activity of another large set.
The important nuance, which is often lost in marketing copy: this does not mean GHK-Cu "switches on 4,000 functions." It means that, in these datasets, GHK behaved like a broad signaling molecule that nudges the cell's overall pattern of gene activity — tending to increase the expression of genes tied to tissue repair, DNA repair and antioxidant defense, and decrease the expression of genes associated with inflammation and cellular stress. In other words, it looks less like a single-target drug and more like a global "reset" signal in the models studied.
Across in-vitro and animal-model studies, GHK and GHK-Cu have been associated with a wide range of activities. Each of the following is drawn from laboratory or preclinical research — none should be read as an established human clinical outcome:
Most therapeutics are designed to hit one receptor or one metabolic pathway. GHK-Cu is interesting precisely because it does the opposite: in the models studied it influences many pathways at once — regeneration, inflammation control, antioxidant defense and repair — apparently by helping cells return to healthier baseline patterns of gene expression. Copper handling is central to this: GHK is a copper carrier, and copper is a required cofactor for enzymes involved in collagen cross-linking, antioxidant defense and angiogenesis. This "signal, not switch" behavior is a recurring theme in the GHK-Cu literature.
This is the part that responsible sourcing pages should say plainly. The in-vitro and animal-model evidence for GHK-Cu is genuinely substantial, spanning gene-expression profiling, fibroblast and skin studies, and wound-healing models over several decades. Topical cosmetic use of copper peptides in skin research is also well documented.
However, large, controlled human clinical trials for many of the broader systemic claims are still limited and expanding. A great deal of the excitement around GHK-Cu comes from mechanistic and preclinical work; confirming which of those effects translate to robust human outcomes — and at what exposures — is an area of ongoing research, not settled fact. Treating preclinical findings as proven human benefits is exactly the mistake this field is prone to, and we won't make it here.
For research applications, identity and purity are what separate a usable reference compound from an unknown. The GHK-Cu we supply to the research community is a lyophilized powder tested to 99% purity by HPLC, with a third-party Certificate of Analysis (COA) available for each lot, strictly for in-vitro laboratory use:
New to handling lyophilized peptides? See our Research Center for storage, reconstitution and COA guidance.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys). It occurs naturally in human plasma and is one of the most-studied copper-binding peptides in regenerative research, first described by Loren Pickart in 1973.
In laboratory studies GHK-Cu behaves like a broad signaling molecule rather than acting on a single receptor. Gene-profiling research reported it can modulate the expression of roughly 4,000 human genes, shifting activity toward tissue-repair genes and away from genes linked to inflammation and cellular aging.
No. GHK-Cu sold for laboratory research is strictly for in-vitro and analytical use. It is not a drug and is not approved for human or animal use. Much of the systemic evidence comes from cell and animal models rather than large human clinical trials.
Research indicates plasma levels of GHK fall with age — reported to decrease markedly from young adulthood into later decades — which has been associated in the literature with a reduced natural capacity for tissue repair.